Biotech Values

[genisi]

Two points on Multaq:

1. In the DIONOSYS (head-to-head vs Amiodarone) trial - Multaq showed to be less effective at suppressing AF but safer.
2. Multaq is contraindicated in patients with severe heart failure (class IV and II-III). It can be used in patients with AF/AFL and no or stable heart failure.

So, Multaq is likely to compete and in time replace Amiodarone because of the safety advantages, imo.